Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders

blonca9
Jun 28, 2024
1 min read

Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that KCC2 inhibition plays in neuronal function.

Recent Posts

See All

Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format

Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma

Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering

Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight